# **Special Issue**

## Fluoroquinolones, 2nd Edition

## Message from the Guest Editors

Fluoroquinolones are effective against many types of bacteria, including those causing respiratory, urinary tract, gastrointestinal, and skin infections, and common fluoroguinolones include ciprofloxacin, levofloxacin, and moxifloxacin. While fluoroguinolones are generally effective and well-tolerated, they are associated with a rare but serious side effect known as fluoroquinoloneassociated disability (FQAD). FQAD encompasses a range of symptoms that can persist long after discontinuation of the medication, including severe fatigue, muscle weakness, joint pain, nerve damage, cognitive difficulties, and psychiatric disturbances. Since the discovery of FQAD, fluoroquinolones have received a "Black Box" label, warning clinicians worldwide to prescribe these antibiotics for uncommon infections or for infections that have not resolved with the utilization of other antibiotic drugs; nevertheless, fluoroquinolones are still among the most prescribed antibiotics worldwide.

We are pleased to invite you to submit a manuscript to this Special Issue of *Pharmaceuticals* on fluoroguinolones

#### **Guest Editors**

Dr. Cecilia Bove

Department of Biological Sciences, York College of Pennsylvania, York, PA 17403, USA

Dr. Nuno Xavier

Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Lisboa, Portugal

## Deadline for manuscript submissions

27 April 2026



## **Pharmaceuticals**

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



mdpi.com/si/254012

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/pharmaceuticals





## **Pharmaceuticals**

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



## **About the Journal**

## Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

#### Editor-in-Chief

#### Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

### **Author Benefits**

### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

## **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

